FLDM:NAS (USA) Also trade in: Germany

Fluidigm Corp

$ 12.83 -0.22 (-1.69%)
Volume: 429,879 Avg Vol (1m): 844,943
Market Cap $: 885.13 Mil Enterprise Value $: 961.79 Mil
P/E (TTM): 0.00 P/B: 8.66
Earnings Power Value -12.04
Net Current Asset Value -2.14
Tangible Book -1.84
Projected FCF -5.38
Median P/S Value 11.22
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 0.55
Equity-to-Asset 0.24
Debt-to-Equity 2.39
Debt-to-EBITDA -5.56
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.07
DISTRESS
GREY
SAFE
Beneish M-Score -2.95
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -29.13%
WACC 10.16%

Profitability & Growth : 3/10

Current vs industry vs history
Operating Margin % -42.64
Net Margin % -52.24
ROE % -141.27
ROA % -21.50
ROC (Joel Greenblatt) % -450.19
3-Year Total Revenue Growth Rate -0.50
3-Year Total EBITDA Growth Rate 2.00
3-Year EPS w/o NRI Growth Rate 7.10

» FLDM's 30-Y Financials

Financials (Next Earnings Date: 2019-05-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:FLDM

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 334516    SIC : 3826
Compare NAS:TTOO AMEX:PTN ISX:PRDA NAS:CTSO ASX:IDX NAS:MGEN MEX:MEDICA B LSE:EKF TSX:AKU.U XMCE:CBAV TSE:4595 NAS:CDNA TSE:4978 NAS:CELC NAS:QTNT TSE:4671 XKRX:086040 NYSE:ENZ LSE:MXCT HKSE:08037
Traded in other countries FLB.Germany
Address 7000 Shoreline Court, Suite 100, South San Francisco, CA, USA, 94080
Fluidigm manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. Fluidigm sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm's revenue comes from the sale of instruments. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of Fluidigm's revenue is generated in the United States and Europe.

Ratios

Current vs industry vs history
PB Ratio 8.66
PS Ratio 4.51
EV-to-EBIT -20.26
EV-to-EBITDA -31.05
EV-to-Revenue 8.46
Current Ratio 3.38
Quick Ratio 3.04
Days Inventory 105.30
Days Sales Outstanding 53.80
Days Payable 28.64

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -19.10

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 1.14
Earnings Yield (Joel Greenblatt) % -4.93

More Statistics

Revenue (TTM) (Mil) $ 112.96
EPS (TTM) $ -1.5
Beta 1.37
Volatility % 39.72
52-Week Range $ 4.65 - 14.9
Shares Outstanding (Mil) 68.99

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y